FOCL stock forecast, quote, news & analysis
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry... Show more
FocalTherics (FOCL) Stock Analysis: Robotic HIFU Expansion Sets the Stage for Q3 Results
Key Takeaways
- FocalTherics (FOCL), formerly EDAP TMS, traded near $4.32, a modest gain of roughly 2.9% over the trailing 30 days following its rebrand to a pure-play robotic focal therapy company.
- The stock has consolidated in a tight range between roughly $4.00 and $4.75, reflecting balanced investor sentiment ahead of a key earnings release.
- Second-quarter 2026 HIFU revenue rose 39% year-over-year to $13.2 million, with gross margin improving to 55.6%.
- Management reiterated full-year 2026 HIFU revenue guidance of $50 million to $54 million, implying 34% to 45% growth.
- Third-quarter 2026 financial results are scheduled for release after the market close on November 5, 2026, making earnings the primary near-term catalyst.
- Operating losses and funding considerations remain the central risks, even as the company targets a 40% revenue CAGR through 2028.
- For deeper detail on valuation, results, and projections, explore FocalTherics Price Targets, Earnings, and Forecast pages.
- To see how automated strategies are positioned across the market, explore Trending AI Robots.
Current Market Snapshot
FocalTherics shares have traded with limited volatility over the past month, holding near $4.32 after closing at roughly $4.20 approximately 30 days earlier. The roughly 2.9% advance reflects a period of consolidation rather than a sharp directional move, with the stock continuing to fluctuate in a band between about $4.00 and $4.75 on comparatively modest daily volume. As a small-cap medical technology name, FOCL is sensitive to clinical data releases, quarterly results, and shifts in healthcare-sector sentiment, factors that have kept traders attentive ahead of the company's upcoming earnings report.
FocalTherics (FOCL) Business Overview and Competitive Position
FocalTherics, whose legal name remains EDAP TMS S.A., develops, manufactures, and markets minimally invasive medical devices powered by proprietary focused ultrasound technology. The company's flagship platform, Focal One® Robotic HIFU, combines advanced imaging, real-time treatment planning, and robotic precision to deliver personalized focal therapy for localized prostate cancer while aiming to preserve urinary and sexual function. In mid-2026, the company adopted the FocalTherics identity and moved its Nasdaq listing from EDAP to FOCL, classifying its legacy lithotripsy (ESWL) and distribution segments as discontinued operations to focus exclusively on high-growth robotic focal therapy. The platform has gained adoption across major academic and community institutions, supported by growing clinical evidence, expanding reimbursement, and early efforts into additional indications.
Recent Developments Driving FOCL
Several verified developments have shaped investor sentiment over recent months. The corporate rebrand and ticker change to FOCL, effective June 1, 2026, sharpened the company's identity around its Focal One platform. In August, FocalTherics reported second-quarter results showing HIFU revenue of $13.2 million, a 39% year-over-year increase, alongside a gross margin of 55.6% and reaffirmed 2026 guidance of $50 million to $54 million. The company also completed a $40 million equity financing to fund commercial expansion, research, and new indications. On October 22, 2026, FocalTherics announced it would report third-quarter results on November 5, 2026, focusing investor attention on the near-term earnings print. Earlier catalysts, including an FDA 510(k) clearance for the latest Focal One evolution and a collaboration with Telix exploring PSMA-PET imaging in robotic HIFU and theranostics, underscore the company's broader clinical and commercial momentum.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. Tickeron offers hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. These bots vary considerably in strategy, holding timeframe, and performance metrics, allowing users to compare approaches that range from short-term momentum models to longer-horizon trend systems. The page is designed to help traders and investors evaluate automated, data-driven tools that complement traditional research. Exploring the section can provide additional perspective on how algorithmic strategies are currently positioned across the market.
2026 Outlook and What Investors Should Watch
The primary near-term event is the third-quarter 2026 earnings release scheduled for November 5, 2026, which will provide a read on HIFU system placements, procedure volumes, gross margin, and whether full-year guidance of $50 million to $54 million remains intact. Investors will also monitor progress toward the company's stated 40% revenue CAGR target through 2028, expansion of its U.S. installed base, and development of newer indications such as BPH and endometriosis. Key risks include continued operating losses, balance-sheet and funding considerations, the pace of reimbursement adoption, and competitive dynamics in the broader prostate cancer treatment market. Analyst expectations remain focused on whether commercial execution can translate rising procedure demand into improved profitability over time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
FOCL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for FOCL turned positive on October 21, 2026. Looking at past instances where FOCL's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 40 of 56 cases where FOCL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +4.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in 185 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In 73 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
FOCL moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for FOCL moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for FOCL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. FOCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: FOCL's P/B Ratio (-60.174) is slightly lower than the industry average of (11.622). P/E Ratio (-3.952) is within average values for comparable stocks, (10.683). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.147) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of minimally invasive medical devices for urological diseases
Industry MedicalDistributors